Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.97)
# 609
Out of 5,117 analysts
234
Total ratings
51.75%
Success rate
10.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $61.86 | +14.78% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $12.81 | -6.32% | 3 | Dec 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $185 → $205 | $169.99 | +20.60% | 12 | Nov 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $8.71 | +118.14% | 5 | Nov 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $178 → $173 | $137.52 | +25.80% | 31 | Nov 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $100.37 | +28.52% | 14 | Oct 16, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $44.30 | +73.81% | 3 | Sep 29, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $40.31 | +95.98% | 5 | Sep 17, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $76.89 | -7.66% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $10.11 | +177.01% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $9.82 | +113.85% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $3.75 | -46.67% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $6.56 | +98.17% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.29 | +656.04% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $22.53 | +144.12% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $26.63 | -9.88% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $78.06 | +8.89% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $23.09 | +16.93% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.78 | +349.88% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $2.45 | +63.27% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $2.58 | +55.04% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $6.57 | +113.09% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.58 | +39.86% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.76 | -20.21% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $2.57 | +444.75% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.24 | +706.45% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $42.82 | -48.62% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $9.53 | +1,458.24% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.95 | +6,189.31% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.07 | +47.42% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $13.61 | +4,661.21% | 6 | May 8, 2020 |
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $61.86
Upside: +14.78%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $12.81
Upside: -6.32%
Jazz Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $185 → $205
Current: $169.99
Upside: +20.60%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $8.71
Upside: +118.14%
Neurocrine Biosciences
Nov 11, 2025
Maintains: Overweight
Price Target: $178 → $173
Current: $137.52
Upside: +25.80%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $100.37
Upside: +28.52%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $44.30
Upside: +73.81%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $40.31
Upside: +95.98%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $76.89
Upside: -7.66%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $10.11
Upside: +177.01%
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $9.82
Upside: +113.85%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $3.75
Upside: -46.67%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $6.56
Upside: +98.17%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.29
Upside: +656.04%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $22.53
Upside: +144.12%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $26.63
Upside: -9.88%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $78.06
Upside: +8.89%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $23.09
Upside: +16.93%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $7.78
Upside: +349.88%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $2.45
Upside: +63.27%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $2.58
Upside: +55.04%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $6.57
Upside: +113.09%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.58
Upside: +39.86%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.76
Upside: -20.21%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $2.57
Upside: +444.75%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.24
Upside: +706.45%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $42.82
Upside: -48.62%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $9.53
Upside: +1,458.24%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.95
Upside: +6,189.31%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.07
Upside: +47.42%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $13.61
Upside: +4,661.21%